CaliPharms Net Income

CaliPharms posts a net income of $-6.4M as of September 2014. That compares with $-110K in the prior-year period — down 5799.0% year over year. That is below the Industrials sector average of $27B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CaliPharms's net income was $-110K. The latest reading is $-6.4M — a 5799.0% year-over-year decrease (period ending September 2014). Use the history and growth charts on this page for a longer lookback.

For Industrials stocks, a net income near $27B is typical. CaliPharms's $-6.4M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of CaliPharms's financial statement story. At $-6.4M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for KGET's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $27B), and (3) consistency with growth and profitability. This page covers the first two; CaliPharms's other metric pages and overview cover the third.